PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2019-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue

NCT03048305

Nasopharyngeal Carcinoma

UNKNOWN

Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma

NCT06770699

Nasopharyngeal Cancinoma (NPC)

ACTIVE_NOT_RECRUITING

PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT

NCT05008796

Head and Neck Squamous Cell Carcinoma Circulating Tumor Cell

UNKNOWN

Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

NCT06762470

Histopathological Diagnosis of Nasopharyngeal Carcinoma Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition

ACTIVE_NOT_RECRUITING

Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma

NCT06367049

Nasopharyngeal Carcinoma Early Diagnosis of Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NPC is a common type cancer in Macau and Southern China. The role of PD-L1 in NPC remains controversial. There many reasons behind these inconsistent findings. We used the SP263 antibody with the standard cut off value of 1% and 5%, which is frequently used for lung cancer and other cancer types. We also plan to include over 150 patients, which will be the largest study in NPC. This will help us to gain insights in NPC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NPC patients

Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.

Radiation

Intervention Type RADIATION

Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation

Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above 18 years of age
* Locally advanced (stage IIIB) or metastatic (stage IV) NPC
* Fresh-frozen tissue samples were available were included
* After treatment with curative surgery or radiotherapy in Macau
* With follow up data were available